Hemostatic gels sales will expand through 2036, with bovine-based gels at 38.4% of material sales and general surgery at 41.7% within the indication segment in 2026. The market is estimated at USD 1.2 billion in 2026 and is forecast to record a 6.6% CAGR between 2026 and 2036.